As Merck’s Keytruda Gains Momentum, Investors Look To The Future
This article was originally published in The Pink Sheet Daily
Keytruda, already the first anti-PD-1 drug to market for melanoma, received FDA breakthrough therapy designation for an indication in lung cancer. The drug’s long-term potential – and upcoming data on a two-drug hepatitis C combo – helped to offset a decline in Merck’s third quarter sales.
You may also be interested in...
Merck looks for growth in key products across emerging markets to keep full-year earnings in check even as it revises down its forecast for revenues.
Priced at $12,500/month, Keytruda will be ready to ship within one week of FDA approval for relapsed melanoma after failure of Yervoy and a BRAF inhibitor. Approval could spur interest in off-label use of PD-1 inhibitor as a first-line treatment.
Centaur-CytoTools introduces novel topical treatment for diabetic foot ulcers in India, for which they see limited direct competition and hope to change the way the difficult-to-treat diabetes complication is managed. Phase III studies are ongoing in Europe.